FDA
-
-
-
-
-
-
-
Protagonist presents one-year ICOTYDE psoriasis data at AAD meeting
-
-
-
-
-
-
-
FDA accepts rusfertide application with priority review for blood disorder
-
-
-
-
-
-
-
Protagonist's (PTGX) Economics Can Change After Takeda Opt-out - Citizens
-
-
-
-
-
-
-
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po
-
-
-
-
-
-
-
Turnstone Biologics Appoints William Waddill to its Board of Directors
-
-
-
-
-
-
-
Pre-Open Stock Movers 04/26: MagnaChip Gains on Deal Talk; Universal Health, GE Dip on Earnings (more...)
-
-
-
-
-
-
-
Pre-Open Stock Movers 10/11: (PTGX) (ADMS) (FLXN) Higher; (HYLN) (LUV) (NET) Lower (more...)
-
325,025 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

